The corporate venture capital fund within the infectious disease-focused Japanese firm says it wants to keep an open mind and to provide long-term support for modalities and technologies that can be an “exciting fit" in 2040.
The corporate venture capital fund within the infectious disease-focused Japanese firm says it wants to keep an open mind and to provide long-term support for modalities and technologies that can be an “exciting fit" in 2040.